Contact
Print
Oncology
PSI is a leading full-service CRO with 800+ staff in Europe (Eastern, Central, Western), the USA and Latin America.
PSI is known and respected for consistently securing fast patient enrollment into clinical trials of all sizes and levels of complexity, across a broad range of indications.
PSI has successfully performed studies in the following cancer indications:
PSI has experience with the following types of cancer therapeutics:
|
|
PSI has worked with liposomal, micellar and nanoparticle formulations.
PSI has managed Phase I, II and III cancer studies.
PSI has run studies in neoadjuvant, adjuvant and advanced disease settings.
Breakdown of PSI Studies by Indication and Phase since 2000:
| Indication | Phase I | Phase II | Phase III | Total |
| Breast cancer | 0 | 7 | 14 | 21 |
| NSCLC | 3 | 8 | 8 | 19 |
| SCLC | 1 | 3 | 0 | 4 |
Colorectal cancer | 1 | 3 | 0 | 4 |
| Ovarian cancer | 0 | 4 | 2 | 6 |
| Pancreatic cancer | 1 | 3 | 2 | 6 |
| Head & neck cancer | 0 | 0 | 2 | 2 |
| Prostate cancer | 1 | 7 | 7 | 15 |
| Hepatic carcinoma | 1 | 1 | 0 | 2 |
| Gastric cancer | 0 | 3 | 0 | 3 |
| Multiple myeloma | 1 | 2 | 2 | 5 |
| Solid tumors | 5 | 1 | 0 | 6 |
| Transitional cell carcinoma | 0 | 1 | 0 | 1 |
| Lymphoma | 1 | 3 | 2 | 6 |
| Leukemia | 1 | 2 | 1 | 4 |
| Renal carcinoma | 1 | 2 | 3 | 6 |
| Bladder cancer | 0 | 0 | 1 | 1 |
| Esophageal cancer | 0 | 0 | 1 | 1 |
| Melanoma | 0 | 0 | 2 | 2 |
| Kaposi's sarcoma | 0 | 1 | 0 | 1 |
| Chemo-induced nausea & vomiting | 0 | 1 | 2 | 3 |
| Thrombocythemia | 1 | 1 | 0 | 2 |
| Radiation-induced mucositis | 0 | 0 | 1 | 1 |
| 18 | 54 | 53 | 125 |